Zacks Investment Management’s Myriad Genetics MYGN Stock Holding History

Zacks Investment Management’s Portfolio MYGN Stock Details MYGN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$465K	Buy	+81,392	New	+$369K	﹤0.01%	521
2019 Q2	–	Sell	-14,351	Closed	-$476K	–	595
2019 Q1	$476K	Buy	+14,351	New	+$437K	0.01%	459
2016 Q4	–	Sell	-13,256	Closed	-$273K	–	698
2016 Q3	$273K	Buy	+13,256	New	+$336K	0.01%	515
2014 Q3	–	Sell	-11,054	Closed	-$430K	–	720
2014 Q2	$430K	Buy	+11,054	New	+$411K	0.02%	483
2013 Q4	–	Sell	-16,088	Closed	-$378K	–	715
2013 Q3	$378K	Sell	16,088 -854	-5%	-$24.3K	0.02%	441
2013 Q2	$455K	Buy	+16,942	New	+$491K	0.02%	327

Other funds holding MYGN

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

VPC

Vestal Point Capital New York $4.28B AUM 239% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Zacks Investment Management's MYGN Position: Q2 2026 in Review

Zacks Investment Management opened a new position in Myriad Genetics (MYGN) in Q2 2026: 81,392 shares worth $465K. The stake represents ﹤0.01% of the portfolio and ranks #521 among its holdings. This is a return to the name: Zacks Investment Management previously reported a position in MYGN as recently as Q1 2019.

Zacks Investment Management first reported a position in MYGN in Q2 2013 and has held it in 6 quarters since. The position peaked at $476K in Q1 2019. 196 funds tracked by Wall St. Rank hold MYGN as of Q2 2026.

Zacks Investment Management held 81,392 shares of Myriad Genetics worth $465K as of Q2 2026.
Myriad Genetics was a new Zacks Investment Management position in Q2 2026.
Myriad Genetics made up ﹤0.01% of Zacks Investment Management's portfolio in Q2 2026, its #521 holding.
Zacks Investment Management first reported a position in Myriad Genetics in Q2 2013 and has held it in 6 quarters since.
Zacks Investment Management's Myriad Genetics position peaked at $476K in Q1 2019.
196 funds tracked by Wall St. Rank held Myriad Genetics as of Q2 2026.

Based on Zacks Investment Management's 13F filing for Q2 2026, filed 13 Aug 2026.